Drug reference

zoster recombinant vaccine

adjuvanted recombinant subunit vaccine · vaccine

adjuvanted recombinant subunit vaccinevaccine

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

This adjuvanted recombinant subunit vaccine contains recombinant VZV glycoprotein E in combination with a novel adjuvant (AS01B) to induce a robust immune response and prevent herpes zoster (shingles).

Indications

prevention of herpes zoster (shingles) in adults aged 50 years or older

Dosing

Adult: two intramuscular doses, administered 2 to 6 months apart

Related guidelines

Stroke and TIA — secondary prevention

AHA · Neurology · 2021

Tobacco-related cancer prevention

ICMR · Oncology · 2021

Cardiovascular disease prevention

ESC · Cardiology · 2021

Primary prevention of cardiovascular disease

AHA · Cardiology · 2019

Infective endocarditis prevention

ADA_DENTAL · Dentistry · 2015

Ask House about zoster recombinant vaccine

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team